Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia (LLAX)

Randomized, Double-blind, Placebo-controlled, Parallel-group Design, Monocentric Study on Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidemia

The purpose of this study is to investigate whether astaxanthin supplementation can impact triglyceride plasmatic concentrations in volunteers presenting mild dyslipidemia.

Study Overview

• Status: Completed
• Conditions: Dyslipidemias
• Intervention / Treatment: Dietary supplement: Placebo; Dietary supplement: Astaxanthin

• Study Type: Interventional
• Enrollment (Actual): 68
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Lille, France, 59020
    • Centre Nutrition Clinique Naturalpha

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 58 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

To be fulfilled at V0:

1. Male and female volunteers, able to read and write, aged from 18 to 60 years inclusive at time of screening.
2. Smokers and no smokers.
3. Subject with a good physical condition confirmed based on the subject's interview and the clinical exam performed by the investigator.
4. Subject with a Body Mass Index (BMI) ≥ 18,5 and < 35 kg/m².
5. Written informed consent provided prior to screening, after receiving and understanding the subject information.
6. Stable body weight (< 3% variation) within the last 3 months prior to screening.

7. Subject registered with the French Social Security, in agreement with the French law on biomedical experimentation.

   To be fulfilled before V1, randomization visit:

8. Subject with fasting triglyceride concentration ≥ 1.2 and < 4 g/l.
9. Subject with fasting serum LDL-cholesterol ≤ 2.2 g/l.

Exclusion Criteria:

To be fulfilled at V0:

1. Subject taking lipid altering drug therapy within 6 weeks prior to screening. Also excluded are supplements known to have significant lipid altering effects, such as:

   • Phytosterols or phytostanols,
   • Red yeast rice extract (Monascus purpureus),
   • Beta-glucans,
   • Omega-3 fatty acids (alpha-linolenic, docosahexaenoic and eicosapentaenoic),
2. Subject using the following medications: systemic corticosteroids (nasal and inhaled corticosteroids are permitted), orlistat, bile acid resins, prescription omega-3 fatty acids, cyclical or non continuous hormone therapy (estrogen or testosterone) excepted stable oestroprogestative or progestative contraception i.e. started at least three months preceding the screening visit.
3. Intake of oestroprogestative or progestative contraception started within less than three months preceding the screening visit.
4. Subject taking antioxidant agents or vitamins within 6 weeks prior to screening.
5. Subject taking astaxanthin-rich foods (red fish and seafood, mostly) or supplements (including krill).
6. Subject following any special diet including, but not limited to liquid, high or low protein, raw food, vegetarian or vegan, etc.
7. Subject with any sensitivity or allergy to any of the products used in this clinical trial.
8. Subject that consume more than three (3) units of alcoholic beverage daily. For the purpose of this study, a unit of alcohol is defined as 400 ml of beer, 200 ml of wine or 50 ml of hard spirits.
9. Subject with known human immunodeficiency virus (HIV) seropositivity.
10. Women who are pregnant or breastfeeding, or planning a pregnancy during the duration of the study.
11. Female subject without efficient contraceptive method: hormonal contraception (including patch, contraceptive ring, etc.), intra-uterine device or other mechanical contraception method (condom or diaphragm) or spermicide for all the duration of the study.
12. Subject treated for type 1 or type 2 diabetes mellitus.
13. Subject with known cardiovascular disease or stroke, except for conditions that are deemed clinically insignificant by the investigator.
14. Subject with symptomatic hypertension, treated or not.
15. Subject treated by antivitamin K.
16. Subject with history of significant gastrointestinal disease such as severe constipation, diarrhea, malabsorptive disease, inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis) and all kind of gastrointestinal surgery.
17. Subject with thyroid dysfunction or treatment for this pathology.
18. Subject with history of severe psychiatric illness which in the opinion of the investigator would interfere with the optimal participation in the study.
19. Subject with history of cancer within 5 years of screening visit (except for successfully treated basal and squamous cell carcinoma of the skin).
20. Subject with any medical contraindication to blood sampling (anemia, clotting defect).
21. Subject practicing intense physical activity (sport, physical exertion at work).
22. Subject with history of drug abuse.
23. Participation to any other clinical trial simultaneously and/or within 1 month prior to screening.
24. Subject who in the opinion of the investigator have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial.
25. Subject of legal age unable of giving consent.
26. Subject deprived of liberty by judicial or administrative decision.
27. Subject of legal age under legal protection.
28. Subject having received over 4500 euros for clinical trial participation within the prior year including the indemnity for the present study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Astaxanthin; Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks	Dietary supplement: Astaxanthin
Placebo Comparator: Placebo; filling agent, in lipid capsules, 2 caps per day, duration 12 weeks	Dietary supplement: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
fasting plasma triglycerides	g/l	0, 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
fasting cholesterol	total cholesterol (g/l)	0, 12 weeks
fasting HDL-cholesterol	g/l	0, 12 weeks
fasting LDL-cholesterol	g/l	0, 12 weeks
apolipoprotein A1	g/l	0, 12 weeks
apolipoprotein B	g/l	0, 12 weeks
apolipoprotein balance	Apolipoprotein B over Apolipoprotein A1 ratio	0, 12 weeks
resting blood pressure	triplicate measure	0, 6, 12 weeks
resting heart rate		0, 6, 12 weeks
fasting glucose	g/l	0, 12 weeks
fasting insulin	mU/l	0, 12 weeks
homeostatic model assessment to quantify insulin resistance (HOMA-IR)	glucose (mg/dl) * insulin(U/l) / 405	0, 12 weeks
fasting adiponectin	flow cytometry	0, 12 weeks
fasting leptin	flow cytometry	0, 12 weeks
fasting ghrelin	flow cytometry	0, 12 weeks
fasting resistin	flow cytometry	0, 12 weeks
phosphatidylcholine hydroperoxides	HPLC/MS	0, 12 weeks
plasmatic concentrations in astaxanthin	HPLC/MS	0, 6, 12 weeks
compliance with study product	accountability of returned used/unused caps	0, 6, 12 weeks
adverse events	number of subjects with adverse events	during the 12 weeks of intervention

Collaborators and Investigators

• Sponsor: Ajinomoto Foods Europe SAS
• Collaborators: Naturalpha; Institut Polytechnique LaSalle Beauvais

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2014
• Primary Completion (Actual): September 1, 2015
• Study Completion (Actual): November 1, 2015

Study Registration Dates

• First Submitted: January 8, 2015
• First Submitted That Met QC Criteria: January 16, 2015
• First Posted (Estimate): January 22, 2015

Study Record Updates

• Last Update Posted (Actual): January 9, 2018
• Last Update Submitted That Met QC Criteria: January 8, 2018
• Last Verified: January 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Dyslipidemias
• Other Study ID Numbers: 2014-A00198-39